| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
3 companies
Michael S Perry is Director at ARMP and has filed Form 4s across 3 companies. Michael S Perry's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $11.4M at current prices.
Historically, Michael S Perry's trades have earned a middling insider score of 55/100 across 6 rated trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of +20.5%.
The biggest single holding is ARWR (~$6.6M) as Director. The ARWR filings lean toward selling, a net 257,350 shares.
Michael S Perry has 31 Form 4 filings on record from March 2015 to August 2026, across 3 companies: Director at Arrowhead Pharmaceuticals (ARWR), 2015–2026; Director at AVITA Medical (RCEL), 2019–2022; Director at Armata Pharmaceuticals (ARMP), 2015–2019.
The 61 reported transactions were 21 stock awards, 19 open-market sales, 10 option or other derivative awards and 7 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $200K and 12 sales worth about $13.1M.
The only open-market purchase was 181,820 shares of ARMP at an average $1.10 on March 22, 2018, about $200K.
The largest open-market sale was 185,000 shares of ARWR at an average $29.41 on September 11, 2019, about $5.4M.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 11,600 | $87.30 | $1,012,680.00 | -9.4% | - | - | |
| Dec 5, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 16,250 | $61.03 | $991,737.50 | -12.4% | +3.5% | - | |
| Nov 21, 2022 | RCEL Avita Medical, Inc. | Director | Sale+OE | 150,000 | $7.18 | $1,077,000.00 | -39.5% | +27.0% | +41.6% | |
| Feb 24, 2022 | RCEL Avita Medical, Inc. | Chief Executive Officer | Sell | 10,812 | $8.74 | $94,496.88 | -3.3% | -39.2% | +38.2% | |
| Jan 3, 2022 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 4,500 | $64.71 | $291,192.40 | -5.0% | -27.7% | -45.0% | |
| Sep 1, 2021 | RCEL Avita Medical, Inc. | Chief Executive Officer | Sell | 11,220 | $20.68 | $232,029.60 | -4.5% | -33.9% | -70.3% | |
| Jun 2, 2021 | RCEL Avita Medical, Inc. | Chief Executive Officer | Sell | 23,000 | $17.33 | $398,590.00 | -9.3% | +16.6% | -67.1% | |
| Jan 4, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 4,000 | $76.09 | $304,360.00 | -4.3% | - | - | |
| Sep 16, 2020 | RCEL Avita Medical, Inc. | Chief Executive Officer | Sell | 47,861 | $27.19 | $1,301,252.95 | -10.1% | - | - | |
| Sep 11, 2020 | RCEL Avita Medical, Inc. | Chief Executive Officer | Sell | 27,128 | $26.08 | $707,581.28 | -6.3% | - | - |